Oncology Specialty Pharmacy Teams Help Ease Financial Burden for Patients

Oncology specialty pharmacy teams play an important role in reducing financial toxicity for patients and ensuring timely access to cancer therapies through financial assistance programs, according to a study published in the Journal of Managed Care & Specialty Pharmacy.
It has been well established that cancer medications are costly and often induce a financial burden for patients. With increasing therapeutic advancements, more patients are living longer and require long-term oral therapies and supportive care management.
Further, there are often significant barriers to access, which can include obtaining prior authorization, lack of time and familiarity, and cost. These often have a negative impact on patients, sometimes resulting in treatment delays and care disruption that can affect outcomes. A previous study found that patient out-of-pocket costs between $100 and $500 were associated with a 32% therapy abandonment rate, the study authors wrote. As shown by this analysis, oncology specialty pharmacy teams can offer ongoing support by enrolling patients in financial assistance programs. 
Using prescription claims from January 2017 to June 2017, the current study evaluated patient out-of-pocket costs after enrollment in manufacturer patient assistance programs (PAPs), co-pay cards, and foundation grants through a quality improvement project at an oncology specialty pharmacy at the University of Chicago Medicine (UCM).
The UCM Specialty Pharmacy, which implemented its oncology specialty services in 2016, is integrated into the health system and supported by 3 pharmacists and 2 ambulatory medication access coordinators. The pharmacists are integrated into the outpatient clinics and serve as an extension of the provider team, performing services such as clinical review for efficacy, medication and disease state education, patient adherence management, consulting with physicians, and providing access to care on a 24/7 basis through a specialty pharmacist on-call program.
In total, there were 233 patients who filled at least 1 specialty pharmacy prescription at UCM Specialty Pharmacy. Of these patients, 75 were enrolled in financial assistance. Over the 6-month period, the total patient cost savings was $314,857, according to the study. Financial assistance was most frequently used for the following medications: peg-filgrastim, dasatinib, abiraterone, filgrastim and filgrastim-sndz, palbociclib, venetoclax, and ruxolitinib.
The analysis looked at 3 interventions: manufacturer PAPs, co-pay cards, and foundation grants. The findings showed that the cost savings of each intervention ranged from $5 to $13,138 for all of the patients who received financial assistance. Additionally, the average days from date of insurance approval to date of financial grant approval was 1.2, according to the study.
“This quality improvement project demonstrates how specialty pharmacists and pharmacy technicians integrated within a health system can perform benefits investigations, assess patient out-of-pocket responsibility, and enroll patients in such programs to alleviate the high cost burden of [oral anticancer medications] and prevent therapy abandonment,” the authors wrote.
Farano JL, Kandah HM. Targeting financial toxicity in oncology specialty pharmacy at a large tertiary academic medical center. Journal of Managed Care & Specialty Pharmacy. 2019. https://doi.org/10.18553/jmcp.2019.25.7.765

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Cancers of the lung, breast, prostate, and colon are most common in adults aged 85 years and older.
Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.
A phase 3 study evaluated the safety and efficacy of oral paclitaxel versus intravenous paclitaxel monotherapy in patients with metastatic breast cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.